BeOne Medicines (ONC) Common Equity (2015 - 2026)

BeOne Medicines (ONC) has reported Common Equity for 12 consecutive years, with $4.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 36.03% year-over-year to $4.8 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 36.03% YoY), while the FY2025 annual figure was $4.4 billion, up 30.88% from the prior year.
• Common Equity rose to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.4 billion in the prior quarter.
• Across five years, Common Equity topped out at $5.8 billion in Q1 2022 and bottomed at $3.3 billion in Q4 2024.
• Historically, Common Equity has averaged $4.1 billion across 5 years, with a median of $3.8 billion in 2023.
• On a YoY basis, Common Equity climbed as much as 44.22% in 2022 and fell as far as 28.52% in 2022.
• BeOne Medicines' Common Equity stood at $4.4 billion in 2022, then retreated by 19.3% to $3.5 billion in 2023, then declined by 5.8% to $3.3 billion in 2024, then jumped by 30.88% to $4.4 billion in 2025, then climbed by 9.15% to $4.8 billion in 2026.
• Business Quant data shows ONC's Common Equity at $4.8 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.